Análise imunológica e genotóxica em Rattus Novergicus da linhagem wistar tratados com ciclofosfamida

Abstract

The development of this work has given up due to the need to better understand the immune system, taking into account the diversity of experimental immunosuppression models as well as the variety of immunological responses and genotoxic differences these, related species, the drug and doses used. Thus, aim of this study was to analyze the effects on the immune system and genotoxic effects in Rattus norvegicus Wistar, after inoculation of the alkylating agent cyclophosphamide (CY). The administration of 50 mg / kg in rodents CY, possible to observe a significant decrease in the parameters of cellularity and relative weight of lymphoid organs. The humoral immunity of rodents has undergone deletion, since the analysis of the antibody titration was performed on the test plate forming cells and hemolysis testing. four inoculations that immunosuppressant and the intervals between the inoculations was determined by recovery of normal levels of the above parameters were performed. Both times the drug was administered, there was a reduction in the number of lymphocytes and neutrophils subsequently decreased, but only the second contact CY was observed immunosuppression. The analysis of the genotoxicity of cyclophosphamide (CY) was analyzed using the comet assay and was of paramount importance because dectamos genomic damage occurring in DNA exposed to different doses of cyclophosphamide (CY), which were 50 mg / kg in the first two phases and 25 mg / kg during the last two phases of the experiment. Furthermore, it was found that the genotoxic effects are cumulative with each CY dose applied, because even being administered in the third phase, the middle concentration (25 mg / kg) of the two inoculations initial CY the damage index does not correspond to half damage indices of the first and second vaccination. However, the analysis and immunologically genotoxicamente rodents, our work will enable testing new therapeutic immunosuppression regimens.